Back

Cardiological monitoring during BTK inhibitor, ICI, and RAF/MEK inhibitor therapy: the single-center prospective registry for cardiovascular events under new cancer therapies (RECENT)

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Caring for the patient with cancer and heart disease: the clinical perspective Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Leni Katharina Seuthe

Cologne University Hospital - Heart Center, Cologne (Germany)

7 More presentations in this session

Presentation thumbnail
Cardiovascular events and consequent risk of death in hematopoietic stem cell transplant recipients
Doctor G. Stronati (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Socioeconomic status and cardiovascular mortality in over 170,000 cancer survivors: a population-based cohort study
Doctor Y. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Routine application of cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy
Mr T. Lerchner (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Safety and effectiveness of sodium-glucose co-transporter 2 inhibitors in active cancer patients with heart failure: results of the observational TOSCA trial
Doctor M. Canale (Lido Di Camaiore, IT)
Abstract Slides Video
Presentation thumbnail
New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.
Doctor N. Osataphan (Chiang Mai, TH)
Abstract Slides Video

Access the full session

Session thumbnail
Caring for the patient with cancer and heart disease: the clinical perspective

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Cardiovascular disease and its association with outcomes in cancer patients treated with immune checkpoint inhibitors
thumbnail
Congress Presentation
Real-world analysis of risk factors for cardiovascular toxicity associated with immune checkpoint inhibitors
thumbnail
Congress Presentation
Cardiovascular risks of PD1 inhibitor therapy in cancer: impact of prior ischemic events on heart failure - a retrospective cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources